The Subject Expert Committee (SEC) of the Indian drug regulator will meet immediately to take up an software by pharma large Dr Reddy’s Laboratories looking for emergency approval for Sputnik V, the Russia-developed coronavirus vaccine. The vaccine has an efficacy of 91.6 per cent.
On February 19, Dr Reddy’s Laboratories had approached the Drug Controller General of India (DGCI) to get approval for the emergency use of Sputnik V.
At 91.6 per cent, Sputnik V has the next efficacy as in comparison with Covid vaccines which can be at present being administered in India. While Oxford-AstraZeneca’s Covishield vaccine, being manufactured by the Serum Institute of India, has an efficacy of round 70 per cent, Bharat Biotech’s Covaxin’s efficacy just isn’t identified.
Sputnik V is one in every of solely three vaccines on the earth with such a excessive efficacy fee, after Pfizer and Moderna vaccines. The two-dose vaccine additionally has most authorisations granted with 26 nations globally. Priced at lower than $10 per dose in worldwide markers, the vaccine has already been administered to greater than 20 lakh individuals worldwide.
In India, the trials are being performed on 1,600 individuals.
The Sputnik vaccine is offered in each liquid and powder kind. The liquid kind must be saved in minus 18 levels. For the powder kind – which may be saved in between 2 and eight levels, stability exams are on.
In September final yr, Dr Reddy’s partnered with the Russian Direct Investment Fund (RDIF) to conduct scientific trials of Sputnik V and for its distribution rights in India.
1.21 crore healthcare and frontline staff in India have been vaccinated in opposition to coronavirus thus far.